

1 **High proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell**  
2 **responses**

3 Annemarie Namuniina<sup>1</sup>, Enoch S Muyanja<sup>2</sup>, Victoria M Biribawa<sup>1</sup>, Brenda A Okech<sup>1</sup>, Aloysius  
4 Ssemaganda<sup>3</sup>, Matt A Price<sup>4,6</sup>, Nancy Hills<sup>5</sup>, Ann Nanteza<sup>7</sup>, Bernard Ssentalo Bagaya<sup>8,9</sup>, Daniela Weiskopf<sup>10</sup>,  
5 Catherine Riou<sup>11,12</sup>, Steven J Reynolds<sup>13,14,15</sup>, Ronald M Galwango<sup>15</sup>, and Andrew D Redd<sup>12,13,14\*</sup>

- 6  
7 1- UVRI-IAVI HIV Vaccine Program, Entebbe, Uganda  
8 2- Emory University, Department of Pathology and Laboratory Medicine  
9 3- Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg,  
10 MB, Canada  
11 4- IAVI, Epidemiology & Biostatistics, University of California San Francisco, San Francisco, USA  
12 5- University of California, San Francisco, Department of Neurology, Department of Epidemiology  
13 and Biostatistics  
14 6- Department of Epidemiology and Biostatistics, University of California San Francisco, San  
15 Francisco, USA  
16 7- Makerere University, College of Veterinary Medicine, Animal Resources & Bio-security, Kampala  
17 Uganda  
18 8- Makerere University, College of Health Sciences, School of Biomedical Sciences, Department of  
19 Immunology and Molecular Biology, Kampala Uganda  
20 9- Makerere University, College of Health Sciences, Integrated Biorepository of H3-Africa-Uganda  
21 (IBRH3AU), COVID-19 Biobank (COV-BANK)  
22 10- Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA,  
23 USA  
24 11- University of Cape Town, Cape Town, South Africa  
25 12- Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town,  
26 South Africa  
27 13- Division of Intramural Research, NIAID, NIH, Baltimore MD, USA  
28 14- Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA  
29 15- Rakai Health Sciences Program, Kalisizo, Uganda

30  
31 Corresponding author: Andrew D. Redd, PhD; [reddandrew@niaid.nih.gov](mailto:redandrew@niaid.nih.gov)

32 Short title: Pre-existing cross-reactive SARS-CoV-2 T-cells in Ugandans

33 Target journal: PLOS Global Health

34

35 Manuscript: 2585 words

36 **Abstract: (234/300 words, unstructured)**

37 The estimated mortality rate of the SARS-CoV-2 pandemic varied greatly around the world with multiple  
38 countries in East, Central, and West Africa having significantly lower rates of COVID-19 related fatalities  
39 than many resource-rich nations with significantly earlier wide-spread access to life-saving vaccines. One  
40 possible reason for this lower mortality could be the presence of pre-existing cross-reactive  
41 immunological responses in these areas of the world. To explore this hypothesis, stored peripheral blood  
42 mononuclear cells (PBMC) from Ugandans collected from 2015-2017 prior to the COVID-19 pandemic  
43 (n=29) and from hospitalized Ugandan COVID-19 patients (n=3) were examined using flow-cytometry for  
44 the presence of pre-existing SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell populations using four T-cell  
45 epitope mega pools. Of pre-pandemic participants, 89.7% (26/29) had either CD4+ or CD8+, or both, SARS-  
46 CoV-2 specific T-cell responses. Specifically, CD4+ T-cell reactivity (72.4%) and CD8+ T-cell reactivity  
47 (65.5%) were relatively similar, and 13 participants (44.8%) had both types of cross-reactive types of T-  
48 cells present. There were no significant differences in response by sex in the population. The rates of  
49 cross-reactive T-cell populations in these Ugandans is higher than previous estimates from resource-rich  
50 countries like the United States (20-50% reactivity). It is unclear what role, if any, this cross-reactivity  
51 played in decreasing COVID-19 related mortality in Uganda and other African countries, but does suggest  
52 that a better understanding of global pre-existing immunological cross-reactivity could be an informative  
53 data of epidemiological intelligence moving forward.

## 54 **Background**

55           The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes Coronavirus disease  
56 2019 (COVID-19), a communicable respiratory disease with symptoms ranging from asymptomatic to  
57 severe acute respiratory distress in humans. Disease presentation is likely affected by a complex array of  
58 factors including host genetics, pre-existing immune status, sex, age, and nutritional status [1].

59           COVID-19 mortality was significantly higher in the western world compared to Eastern, Central,  
60 and West Africa, and this was true despite the fact that broad access to life-saving COVID-19 vaccines was  
61 inequitably delayed for much of Africa. The global excess mortality rate between January 2020 to  
62 December 2021 has been estimated to be 120.3 deaths per 100,000 ( $10^5$ ) people, but this rate varied  
63 widely from  $>500$  per  $10^5$  people in some countries in Eastern Europe to no COVID-related deaths in  
64 countries with total isolation strategies [2]. While excess mortality was influenced by many factors, the  
65 trends suggest that countries in West, Central, and East Africa were generally protected from the worst  
66 COVID-19-related mortality. For example, during this period the estimated increase in mortality in Uganda  
67 was 93.5 per  $10^5$  people, whereas the rate was 179.3 per  $10^5$  people in the United States, 227.4 per  $10^5$   
68 people in Italy, and a shocking 647.3 per  $10^5$  people in Bulgaria [2]. While there are certainly many social,  
69 demographic, and equity factors that influence these estimates, it is likely that levels of underlying  
70 immunological cross-reactivity to SARS-CoV-2 could also affect mortality.

71           A pre-existing immune response to other circulating human common cold coronaviruses  
72 (hCCCoV) is thought to decrease the severity of COVID-19. In one study, the presence of immunoglobulin  
73 G (IgG) antibodies against the SARS-CoV-2 receptor binding domain (RBD) and pre-existing common cold  
74 coronaviruses were tested in hospitalized patients, and those with high IgG levels had milder disease  
75 compared to those with low or no detectable IgG [3]. A study in the United States found that individuals  
76 who had a known hCCCoV infection the year before the SARS-CoV-2 pandemic had significantly lower  
77 rates of mortality and severe disease compared to individuals without previous infection the year before  
78 [4]. Furthermore, a recent study examined pre-existing anti-SARS-COV-2 humoral responses among  
79 populations in France and several African countries and found that pre-pandemic African samples were  
80 approximately ten times more likely to be serologically reactive to SARS-CoV-2 compared to the French  
81 participants [5].

82           In addition to antibody responses, individuals with a high level of pre-existing memory CD4+ T-  
83 cells that are cross-reactive with SARS-CoV-2 may mount a faster and stronger immune response, thereby  
84 limiting disease severity [6]. It has been proposed that SARS-CoV-2-specific T-cells in non-exposed  
85 individuals originate from memory T-cells derived from previous hCCCoV exposure, which is common in

86 the human population [7,8]. Several studies have observed that 20-50% of people who had not been  
87 exposed to SARS-CoV-2 had presence of cross-reactive CD4+ and/or CD8+ T-cells, a phenomenon thought  
88 to occur due to sequence similarity between immunodominant coronavirus epitopes [9–13]. In the United  
89 States, Grifoni et. al. observed cross-reactivity in up to 50% of donor blood samples obtained between  
90 2015 and 2018, prior to the appearance of SARS-CoV-2 in the human population [11]. T-cell cross-  
91 reactivity was greatest against proteins other than the SARS-CoV-2 spike protein, but T-cell cross-reactivity  
92 against spike was also observed. The majority of SARS-CoV-2 T-cell reactivity was associated with CD4+ T-  
93 cells, with a minor contribution from CD8+ T-cells. In the Netherlands CD4+ T-cell cross-reactivity against  
94 SARS-CoV-2 spike peptides was observed in 10% of unexposed individuals, while reactivity to SARS-CoV-2  
95 non-spike peptides was seen in 20% of unexposed individuals [10]. A study in Germany found cross-  
96 reactive T-cell responses to spike peptides in 34% of SARS-CoV-2 unexposed individuals [9]. Similarly, T-  
97 cell cross-reactivity to nucleocapsid protein non-structural protein (nsp7 or nsp13) was found in 50% of  
98 individuals with no history of SARS, COVID-19, or contact with SARS or COVID-19 patients in a study carried  
99 out in Singapore [12,14].

100           Given the lower COVID-19 mortality noted in many parts of Africa and the expected role that pre-  
101 existing cross-reactive immunity may have on disease severity, this study aimed to investigate the  
102 presence and magnitude of SARS-CoV-2 cross-reactive T-cells in pre-pandemic Ugandans.

103

## 104 **Methods**

### 105 **Study scope and design:**

106           Frozen peripheral blood mononuclear cells (PBMC) collected during the Simulated Vaccine  
107 Efficacy Trial (SIVET) were used for this analysis. The goal of the SIVET study was to assess whether people  
108 from Ugandan fishing communities could be enrolled, vaccinated, and retained in a simulated vaccine  
109 efficacy trial using licensed Hepatitis B and Typhoid vaccines in place of experimental vaccines (manuscript  
110 in preparation). Briefly, PBMC were collected from participants aged 18 to 49 years between 2015-2017  
111 from one fishing community in Entebbe along the shores of Lake Victoria before the COVID-19 pandemic.  
112 40ml of blood was drawn and PBMCs isolated by density gradient centrifugation and stored in liquid  
113 nitrogen at 10 million cells per vial. As part of the SIVET study, participants were tested for HIV,  
114 schistosomiasis, and Hepatitis B. The testing kits used for HIV were Determine, StatPak and Unigold, for  
115 schistosomiasis Kato Katz was used, and Hepatitis B testing was performed with VIDAS® HBs Ag Ultra,  
116 VIDAS® Anti-HBs Total II, and VIDAS® Anti-HBc Total II assays. Participants provided written informed  
117 consent to participate in the study, and agreed to the use of their samples in future related research

118 studies. All samples were collected and processed >1 year before the emergence of SARS-CoV-2. For this  
119 study, we used 28 samples from participant enrollment visits, and 1 participant follow up visit, six months  
120 later.

121 In addition, a group of Ugandan patients hospitalized due to complications from COVID-19, were  
122 included as positive controls. 8ml of blood was collected, anonymized, and PBMC ( $5 \times 10^6$ ) were isolated  
123 by density gradient centrifugation and stored in liquid nitrogen. No demographics data was collected from  
124 patients.

#### 125 **Ethical approval**

126 The study was approved by the National Council for science and technology (NCST) and original  
127 SiVET study was also approved by the Uganda Virus Research Institute Research and Ethics Committee  
128 (UVRI REC), GC/127/841. Participants provided written informed consent to participate in the study.

#### 129 **Determination of Cell viability**

130 10 million PBMC ( $10 \times 10^6$  cells/ml) were thawed in a 37°C water bath for one minute. Before  
131 completion of thawing, the cells were transferred from the water bath to a 50ml sterile tube containing  
132 10ml R10 media (complete RPMI with 10% fetal calf serum) and 20µL Dnase (20µl/10ml). The mixture was  
133 spun for at 1200 rpm (revolution per minute) for seven min at 4°C. The supernatant was discarded and  
134 cells were re-suspended in 1ml of R10 media and cell concentration was determined by examining 20µl  
135 (1:1) of a mixture of PBMC/Trypan blue (0.4%) on a hemocytometer.

#### 136 **Activation Induced cell Marker (AIM) assay**

137 The previously described SARS-CoV-2 epitope MegaPool (MP) preparations were used to examine  
138 for possible reactive T-cell populations [10]. A detailed description on the T-cell predictions carried is  
139 available in the following manuscript [15].

140 The AIM assay was used to detect the antigen specific T-cells responses after PBMC stimulation  
141 [16,17]. Briefly, the MP used targeted CD4+ T-cells with spike-specific epitopes (CD4\_S; n=253) or non-  
142 spike epitopes (CD4\_R, n=221). Additionally, CD8+ T-cell responses were examined using the CD8\_A and  
143 CD8\_B epitopes which were estimated to interact with the 12 most common HLA class I A and B alleles  
144 [10,11].

145 T-cell activation was determined as described previously [11]. Briefly, cells were cultured for 24  
146 hours in 96-well U bottom plates with  $1.5 \times 10^6$  PBMC per well in the presence of SARS-CoV-2 specific MPs  
147 (1 mg/ml). A stimulation with an equimolar amount of DMSO was used as the negative control, while  
148 Phytohemagglutinin (PHA, Roche, 1 mg/ml) and the combined CD4 and CD8 Cytomegalovirus MP (CMV,  
149 1 mg/ml) were used as positive controls, as previously described.

## 150 **Flow Cytometry**

### 151 PBMC immune cell phenotyping

152 After stimulation, cells were washed in 200µl PBS at 1400rpm at 4°C for 2 min. For the surface  
153 stain, 1.5 x10<sup>6</sup> PBMCs were resuspended in 100 µl Magnetic-Activated Cell Sorting (MACS) buffer and  
154 stained with antibody cocktail for 30 min at 4°C in the dark (Supplemental Table S1). Following cell surface  
155 staining, cells were washed twice with MACS buffer. Cells were resuspended in 100 µl PBS and kept at 4°C  
156 before acquiring on the BD LSRII SORP flow cytometer (BD Biosciences).

### 157 Flow cytometer gating

158 Following acquisition T-cell populations were interrogated as shown in the gating strategy to  
159 identify reactive CD4+ and CD8+ T-cell populations (Supplementary Figure S1). Briefly, cells were initially  
160 gated according to acquisition time to remove artifacts like air bubbles or clogs. The CD3+ cell population  
161 was then selected via Forward Scatter (FSC) and Side Scatter (SSC) and segregated according to CD3  
162 expression to select lymphocytes. This was followed by singlet gating to remove doublets. This was further  
163 followed by gating on live cells. The live cells were divided into CD4+ and CD8+ populations and examined  
164 for activation by the Antigen Induced Markers (AIM) CD137+, OX40+ for CD4+ T-cells and CD69+, CD137+  
165 for CD8+ T-cells, which were both presented in percentages of total CD4+ or CD8+ T-cells. An average  
166 number of 150,000 cells was acquired. Responses for both CD4+ and CD8+ cells were examined for all four  
167 megapools.

### 168 **Data analysis**

169 Data analysis was done using Flowjo (version 10.8, FlowJo LCC, Ashland, OR, USA), Stata (version  
170 17.0; College Station, TX, USA), and GraphPad Prism (version 9; GraphPad Software Inc, San Diego, CA,  
171 USA). Initially, responsiveness was visually examined for all samples, and any sample with no visual  
172 reactivity for a given MP was set at 0%. For all responders, total CD4+ and CD8+ T-cell response was  
173 calculated by subtracting the percentage of activated positive cell responses after SARS-CoV-2 MP  
174 stimulation from the percentage of cell responses after DMSO stimulation. The lowest value across the  
175 four SARS-CoV-2 peptides was used if the percentage of AIM positive cell responses after DMSO  
176 stimulation was zero.

177

## 178 **Results**

179 PBMC samples from our comparison group of actively hospitalized COVID-19 patients were  
180 initially analyzed for SARS-CoV-2 T-cell reactivity. Five samples were originally examined, but two were  
181 excluded for low CD4 % and poor CD4 staining, leaving only three for final analysis (Figure 1, Supplemental

182 Table S2). All three had both CD4+ and CD8+ reactive T-cell populations, although not all patients  
183 responded to all four MPs tested (Supplemental Table S2).

184 The pre-pandemic analysis data set (n=29 participants) included 21 males (72%) with participants  
185 being younger with a median age of 27 years (Table 1). Samples from these participants were collected  
186 between Dec 2015 and May 2017, and were from fishing communities on the shores of Lake Victoria.  
187 These communities tend to be crowded with a significant amount of migration in and out of the area  
188 throughout the year. All participants were HIV negative since the original SiVET study aimed to recruit  
189 only HIV-uninfected individuals. Out of the 29 participants, four people (13.8%) were infected with  
190 Schistosomiasis, and no cases of hepatitis infection were observed. Per the original study protocol, those  
191 participants with Hepatitis B test results suggesting pre-existing immunity to Hepatitis B (i.e., previously  
192 vaccinated before joining the study) were not vaccinated at enrolment.

193 In the pre-pandemic samples (n=29), it was found that 44.8%, 58.6%, 31.0%, and 41.4% of  
194 participants had a detectable CD4+ T-cell response to the CD4\_R (non-spike), CD4\_S (spike), CD8\_A, and  
195 CD8\_B peptide pools, respectively (Figure 2A and Table 2). Furthermore, it was revealed that 72.4% (21)  
196 of participants had CD4+ T-cell response to at least one MP, and 17.2% of individuals were responsive to  
197 all four MP tested (Table 2).

198 CD8+ T-cell reactivity was slightly lower for each MP tested with 17.2%, 31.0%, 20.7%, and 27.6% of  
199 individuals having reactivity to the CD4\_R (non-spike), CD4\_S (spike), CD8\_A, and CD8\_B peptide pools,  
200 respectively (Figure 2B and Table 2). It was found that 65.5% (19) of participants had some CD8+ T-cell  
201 response to at least one MP, and 10.3% of individuals were responsive to three of the four MP tested  
202 (Table 2). No individuals had reactive CD8+ T-cells to all four MP tested.

203 Taken together these data demonstrate that 89.7% (26/29) of this Ugandan population had some  
204 detectable T-cell response (either CD4+ or CD8+) pre-pandemic, and 44.8% (13/29) had both CD4+ and  
205 CD8+ reactive T-cells (Table 2). In addition, the responsiveness was similar in both males and females in  
206 this cohort (Table 3).

207

## 208 **Discussion**

209 There is a need to investigate the cause of disproportionate COVID-19 disease severity in sub-  
210 Saharan Africa as compared to western countries. In this study, cross-reactive T-cell responses to SARS-  
211 CoV-2 were observed in 90% of adult Ugandans in samples collected between Dec 2015 and May 2017,  
212 which was well before the onset of the pandemic. It has been speculated that these cross-reactive  
213 immunological responses are due to exposure to hCCCoVs that share sequence homology and structure



214 with SARS-CoV-2 [8,11]. T-cell derived immunity plays a critical role in our full immunological response to  
215 novel pathogens. It has been shown that participants with pre-existing CD4 T-cell reactivity were able to  
216 mount a faster spike-specific CD4 and antibody response following subsequent COVID-19 vaccination [18].  
217 It is possible that this rapid memory T-cell response results in a more protective response in the event a  
218 person becomes exposed to SARS-CoV-2. However, it should be pointed out that some studies have  
219 suggested that the presence of cross-reactive T-cell responses may not offer protection and could cause  
220 greater disease severity in COVID-19 patients [19]. Either way, the relatively high proportion of Ugandans  
221 with cross-reactive T-cells demonstrated here suggest these pre-existing responses might have been more  
222 prevalent in some African populations compared to the western world where mortality rates were  
223 significantly higher [9–11].

224 It should be noted that previous cross-reactivity studies in African populations have focused on  
225 humoral responses, whereas this study focused on T-cell responses. However, other studies have shown  
226 that when compared to antibodies and CD8+ T-cells, SARS-CoV-2-specific CD4+ T-cells had the strongest  
227 association with reduced COVID-19 disease severity [20]. In addition, the absence of SARS-CoV-2-specific  
228 CD4+ T-cells was linked to severe or fatal COVID-19 infections [9]. These findings of a higher proportion  
229 of cross-reactive T-cell responses in Ugandans is supported by the finding that pre-exposure samples from  
230 Central, East, and Western Africa were more likely to have cross-reactive antibody responses to SARS-  
231 CoV-2 than comparable samples from France and USA [5,21].

232 This study had several limitations. The sample size of the study was relatively small due to limited  
233 sample availability and issues with low CD4+ cell percentage after cell acquisition. However, the sample  
234 size is comparable to other similar studies from resource-rich countries. Additionally, it was not possible  
235 to further characterise responses in memory T-cell subsets because the cell number and total events  
236 collected were too low to accurately measure the rare events in both COVID+ and pre-pandemic samples.  
237 Finally, previous exposure to other hCCoVs was not examined in this study.

238 In summary, high levels of both SARS-CoV-2 specific CD4+ and CD8+ T-cell responses was observed  
239 in this group of Ugandans well before the COVID-19 pandemic. Further work is needed to fully elucidate  
240 the role that these cross-reactive responses may have played in the relatively low COVID-19 related  
241 mortality rates in some areas of Africa

242  
243 **Funding information:** This work was supported by NIH contract 75N93019C00065 (A.S, D.W), and in part  
244 by the Division of Intramural Research, NIAID, NIH. The authors wish to acknowledge the support from  
245 the University of California, San Francisco’s International Traineeships in AIDS Prevention Studies

246 (ITAPS), U.S. NIMH, R25MH123256. Funding for the original SIVET was provided by IAVI. This work was  
247 made possible by generous support from the United States Agency for International Development  
248 (USAID). The full list of IAVI donors is available at [www.iavi.org](http://www.iavi.org). The contents are the responsibility of  
249 the authors and do not necessarily reflect the views of USAID or the United States Government

250

251 **Acknowledgements:** The authors would like to thank the study participants and UVRI-IAVI study staff.

252

253 **Data availability:** Anonymized versions of the data presented here is available upon request

254 ([reddandrew@niaid.nih.gov](mailto:redandrew@niaid.nih.gov)) and pending approval of all pertinent review committees.

255

256 **Competing interests:** LJI has filed for patent protection for various aspects of T cell epitope and vaccine  
257 design work.

258

259 **References:**

- 260 1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019  
261 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* (London, England)  
262 [Internet]. *Lancet*; **2020** [cited 2023 Jan 2]; 395(10223):507–513. Available from:  
263 <https://pubmed.ncbi.nlm.nih.gov/32007143/>
- 264 2. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-  
265 related mortality, 2020-21. *Lancet* (London, England) [Internet]. *Lancet*; **2022** [cited 2023 Jan 2];  
266 399(10334):1513–1536. Available from: <https://pubmed.ncbi.nlm.nih.gov/35279232/>
- 267 3. Cugno M, Meroni PL, Consonni D, et al. Effects of Antibody Responses to Pre-Existing  
268 Coronaviruses on Disease Severity and Complement Activation in COVID-19 Patients.  
269 *Microorganisms* [Internet]. *Microorganisms*; **2022** [cited 2023 Jan 2]; 10(6). Available from:  
270 <https://pubmed.ncbi.nlm.nih.gov/35744709/>
- 271 4. Sagar M, Reifler K, Rossi M, et al. Recent endemic coronavirus infection is associated with less-  
272 severe COVID-19. *J Clin Invest* [Internet]. *J Clin Invest*; **2021** [cited 2023 Jan 2]; 131(1). Available  
273 from: <https://pubmed.ncbi.nlm.nih.gov/32997649/>
- 274 5. Souris M, Tshilolo L, Parzy D, et al. Pre-Pandemic Cross-Reactive Immunity against SARS-CoV-2  
275 among Central and West African Populations. *Viruses* [Internet]. *Viruses*; **2022** [cited 2023 Jan 2];  
276 14(10). Available from: <https://pubmed.ncbi.nlm.nih.gov/36298814/>
- 277 6. Alefishat E, Jelinek HF, Mousa M, Tay GK, Alsafar HS. Immune response to SARS-CoV-2 variants: A  
278 focus on severity, susceptibility, and preexisting immunity. *J Infect Public Health* [Internet].  
279 Elsevier; **2022** [cited 2023 Jan 2]; 15(2):277. Available from: [/pmc/articles/PMC8757655/](https://pubmed.ncbi.nlm.nih.gov/36298814/)
- 280 7. Kundu R, Narean JS, Wang L, et al. Cross-reactive memory T cells associate with protection  
281 against SARS-CoV-2 infection in COVID-19 contacts. *Nat Commun* [Internet]. *Nat Commun*; **2022**  
282 [cited 2023 Jan 2]; 13(1). Available from: <https://pubmed.ncbi.nlm.nih.gov/35013199/>
- 283 8. Mateus J, Grifoni A, Tarke A, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in  
284 unexposed humans. *Science* [Internet]. *Science*; **2020** [cited 2023 Jan 2]; 370(6512). Available  
285 from: <https://pubmed.ncbi.nlm.nih.gov/32753554/>
- 286 9. Braun J, Loyal L, Frentsch M, et al. SARS-CoV-2-reactive T cells in healthy donors and patients  
287 with COVID-19. *Nature* [Internet]. *Nature*; **2020** [cited 2023 Jan 2]; 587(7833):270–274. Available  
288 from: <https://pubmed.ncbi.nlm.nih.gov/32726801/>
- 289 10. Weiskopf D, Schmitz KS, Raadsen MP, et al. Phenotype and kinetics of SARS-CoV-2-specific T cells  
290 in COVID-19 patients with acute respiratory distress syndrome. *Sci Immunol* [Internet]. *Sci*

- 291 Immunol; **2020** [cited 2023 Jan 2]; 5(48). Available from:  
292 <https://pubmed.ncbi.nlm.nih.gov/32591408/>
- 293 11. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in  
294 Humans with COVID-19 Disease and Unexposed Individuals. *Cell* [Internet]. *Cell*; **2020** [cited 2021  
295 Dec 1]; 181(7):1489-1501.e15. Available from: <https://pubmed.ncbi.nlm.nih.gov/32473127/>
- 296 12. Bert N Le, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19  
297 and SARS, and uninfected controls. *Nature* [Internet]. *Nature*; **2020** [cited 2023 Jan 2];  
298 584(7821):457–462. Available from: <https://pubmed.ncbi.nlm.nih.gov/32668444/>
- 299 13. Nelde A, Bilich T, Heitmann JS, et al. SARS-CoV-2-derived peptides define heterologous and  
300 COVID-19-induced T cell recognition. *Nat Immunol* [Internet]. *Nat Immunol*; **2021** [cited 2023 Jan  
301 2]; 22(1):74–85. Available from: <https://pubmed.ncbi.nlm.nih.gov/32999467/>
- 302 14. Swadling L, Diniz MO, Schmidt NM, et al. Pre-existing polymerase-specific T cells expand in  
303 abortive seronegative SARS-CoV-2. *Nature* [Internet]. *Nature*; **2022** [cited 2023 Jan 2]; 601(7891).  
304 Available from: <https://pubmed.ncbi.nlm.nih.gov/34758478/>
- 305 15. Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A Sequence Homology and  
306 Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2.  
307 *Cell Host Microbe* [Internet]. *Cell Host Microbe*; **2020** [cited 2023 Jan 2]; 27(4):671-680.e2.  
308 Available from: <https://pubmed.ncbi.nlm.nih.gov/32183941/>
- 309 16. Bowyer G, Rampling T, Powlson J, et al. Activation-induced Markers Detect Vaccine-Specific CD4<sup>+</sup>  
310 T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials. *Vaccines*  
311 [Internet]. *Vaccines* (Basel); **2018** [cited 2023 Jan 2]; 6(3). Available from:  
312 <https://pubmed.ncbi.nlm.nih.gov/30065162/>
- 313 17. Reiss S, Baxter AE, Cirelli KM, et al. Comparative analysis of activation induced marker (AIM)  
314 assays for sensitive identification of antigen-specific CD4 T cells. *PLoS One* [Internet]. *PLOS*; **2017**  
315 [cited 2023 Jan 2]; 12(10). Available from: [/pmc/articles/PMC5655442/](https://pubmed.ncbi.nlm.nih.gov/30065162/)
- 316 18. Mateus J, Dan JM, Zhang Z, et al. Low-dose mRNA-1273 COVID-19 vaccine generates durable  
317 memory enhanced by cross-reactive T cells. *Science* [Internet]. *Science*; **2021** [cited 2023 Jan 2];  
318 374(6566). Available from: <https://pubmed.ncbi.nlm.nih.gov/34519540/>
- 319 19. Lin CY, Wolf J, Brice DC, et al. Pre-existing humoral immunity to human common cold  
320 coronaviruses negatively impacts the protective SARS-CoV-2 antibody response. *Cell Host*  
321 *Microbe* [Internet]. *Cell Host Microbe*; **2022** [cited 2023 Jan 2]; 30(1):83-96.e4. Available from:  
322 <https://pubmed.ncbi.nlm.nih.gov/34965382/>

- 323 20. Peng Y, Mentzer AJ, Liu G, et al. Broad and strong memory CD4+ and CD8+ T cells induced by  
324 SARS-CoV-2 in UK convalescent individuals following COVID-19. *Nat Immunol* [Internet]. *Nat*  
325 *Immunol*; **2020** [cited 2023 Jan 2]; 21(11):1336–1345. Available from:  
326 <https://pubmed.ncbi.nlm.nih.gov/32887977/>
- 327 21. Tso FY, Lidenge SJ, Peña PB, et al. High prevalence of pre-existing serological cross-reactivity  
328 against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa. *Int*  
329 *J Infect Dis* [Internet]. *Int J Infect Dis*; **2021** [cited 2023 Jan 2]; 102:577–583. Available from:  
330 <https://pubmed.ncbi.nlm.nih.gov/33176202/>
- 331

**Table 1. Demographic characteristics of 29 non-COVID patients\***

Characteristic	n	(%)
Age, median (IQR)	27	(24-30)
Sex		
Female	8	(27.6)
Male	21	(72.4)
Education level		
Primary	9	(31.0)
S1 - S4	8	(27.6)
S5 - S6	7	(24.1)
Tertiary non-University	5	(17.2)
Positive for hepatitis	0	
Positive for HIV	0	
Positive for schistosomiasis infection	4	(13.8)

medRxiv preprint doi: <https://doi.org/10.1101/2023.01.16.23284626>; this version posted January 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

\* Demographic data were not available for COVID+ subjects (n=3)

**Table 2. CD4+ and CD8+ T cell responses after stimulation for pre-pandemic participants**

<i>Pre-pandemic cohort, n=29</i>	<b>CD4+ T cell Reactivity</b>	<b>% CD4+ Reactivity</b>	<b>CD8+ T cell Reactivity</b>	<b>% CD8 Reactivity</b>
<i>CD4_Non-spike</i>	13	44.8%	5	17.2%
<i>CD4_Spike</i>	17	58.6%	9	31.0%
<i>CD8_A</i>	9	31.0%	6	20.7%
<i>CD8_B</i>	12	41.4%	8	27.6%
<i>Total Pools Reactive</i>				
<i>0</i>	8	27.6%	10	34.5%
<i>1</i>	6	20.7%	9	31.0%
<i>2</i>	5	17.2%	5	17.2%
<i>3</i>	5	17.2%	3	10.3%
<i>4</i>	5	17.2%	0	0.0%
	<b>No Reactive T cells</b>	<b>CD4+ T Cell reactive only</b>	<b>CD8+ T cells reactive only</b>	<b>Both T cells reactive</b>
<i># of participants</i>	3	9	4	13
<i>% of participant</i>	10.3%	31.0%	13.8%	44.8%

**Table 3. Gender and T Cell responses**


Gender stratification (n=29)					
Status at visit	Male [n=21]		Female [n=8]		p-value*
	n	(%)	n	(%)	
<b>Any CD4 or CD8 response at either visit</b>	18	(85.7)	8	(100.0)	0.54
<b>CD4-R [Non-spike]</b>					
Response	12	(57.1)	2	(25.0)	0.21
<b>CD4-S [Spike]</b>					
Response	15	(71.4)	5	(62.5)	0.67
<b>CD8-A</b>					
Response	9	(42.9)	5	(62.5)	0.43
<b>CD8-B</b>					
Response	13	(61.9)	5	(62.5)	1.00

\* p-values calculated using Fisher's Exact test


medRxiv preprint doi: <https://doi.org/10.1101/2023.01.16.23284626>; this version posted January 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Figure 1:

A)



B)




medRxiv preprint doi: <https://doi.org/10.1101/2023.01.16.23284626>; this version posted January 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Figure 1: CD4+ (A) and CD8+ (B) T cell responses in COVID-19 hospitalized patients (n=3). Reactive cell percentages of total CD4+ or CD8+ T cells are shown for CD4\_Non-spike, CD4\_Spike, CD8\_A, CD8\_B, and CMV megapools for both T cell populations.

Figure 2:

A)



B)




Figure 2: CD4+ (A) and CD8+ (B) T cell responses in pre-pandemic Ugandan PBMC samples (n=29). Reactive cell percentages of total CD4+ or CD8+ T cells are shown for CD4\_Non-spike, CD4\_Spike, CD8\_A, CD8\_B, and CMV megapools for both T cell populations.




**Supplementary Table S1: AIM antibodies used for cell staining**

	Membrane Antibody	Fluorochrome	Clone/vendor/catalog
1	CD45RA	BV421	HI100/Biolegend/304130
2	CD14	V500	M5E2/BD/561391
3	CD19	V500	HIB19/BD/561121
4	Live/Dead		
5	CD8	BV650	RPA-T8/BioLegend/301042
6	CD4	PE-CF594	RPA-T4RUO/BD/62316
8	CCR7	FITC	G043H7/Biolegend/353216
9	CD69	PE	FN50/BD/555531
10	OX40	PE-Cy7	Ber-ACT35/Biolegend/350012
11	CD137	APC	4B4-1/BioLegend/309810
12	CD3	AF700	UCHT1/eBioscience/56-0038-42

medRxiv preprint doi: <https://doi.org/10.1101/2023.01.16.23284626>; this version posted January 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

**Supplementary Table S2: Hospitalized COVID + samples**

<i>COVID cohort, n=3</i>	CD4+ T cell Reactivity	% CD4+ Reactivity	CD8+ T cell Reactivity	% CD8 Reactivity
<i>CD4_Non-spike</i>	2	66.7%	1	33.3%
<i>CD4_Spike</i>	2	66.7%	2	66.7%
<i>CD8_A</i>	3	100.0%	3	100.0%
<i>CD8_B</i>	3	100.0%	1	33.3%
<i>Total Pools Reactive</i>				
<i>0</i>	0	0.0%	0	0.0%
<i>1</i>	0	0.0%	1	33.3%
<i>2</i>	1	33.3%	1	33.3%
<i>3</i>	0	0.0%	0	0.0%
<i>4</i>	2	66.7%	1	33.3%



**Supplementary Figure S1: Gating strategy (A-F) for detection of SARS-CoV-2 reactive CD4+ and CD8+ cells after PBMC stimulation:** Time gating was done to eliminate any artifact like air bubble (A), followed by a selection of lymphocyte population (B), and singlets (C). Live CD3+ cells were selected (D-E), then divided into CD4+ and CD8+ cells (F). Within CD4 and CD8 subsets, antigen-specific T cells were established through the upregulation of activation-induced markers OX40, CD69, and CD137. Percentages of OX40+CD137+ double-positive cells within the CD4 gate (F-i) and percentage of CD69+CD137+ within the CD8 gate (F-ii) showing activated cells, were gated out to be used for further analysis